van Leeuwen D - Search Results

1

Novel point mutation in the extracellular domain of the granulocyte colony-stimulating factor (G-CSF) receptor in a case of severe congenital neutropenia hyporesponsive to G-CSF treatment.

Ward AC, van Aesch YM, Gits J, Schelen AM, de Koning JP, van Leeuwen D, Freedman MH, Touw IP. Ward AC, et al. Among authors: van aesch ym, van leeuwen d. J Exp Med. 1999 Aug 16;190(4):497-507. doi: 10.1084/jem.190.4.497. J Exp Med. 1999. PMID: 10449521 Free PMC article.

2

Signaling mechanisms coupled to tyrosines in the granulocyte colony-stimulating factor receptor orchestrate G-CSF-induced expansion of myeloid progenitor cells.

Hermans MH, van de Geijn GJ, Antonissen C, Gits J, van Leeuwen D, Ward AC, Touw IP. Hermans MH, et al. Among authors: van de geijn gj, van leeuwen d. Blood. 2003 Apr 1;101(7):2584-90. doi: 10.1182/blood-2002-07-2062. Epub 2002 Dec 5. Blood. 2003. PMID: 12468431 Free article.

3

Proliferation signaling and activation of Shc, p21Ras, and Myc via tyrosine 764 of human granulocyte colony-stimulating factor receptor.

de Koning JP, Soede-Bobok AA, Schelen AM, Smith L, van Leeuwen D, Santini V, Burgering BM, Bos JL, Lowenberg B, Touw IP. de Koning JP, et al. Among authors: van leeuwen d. Blood. 1998 Mar 15;91(6):1924-33. Blood. 1998. PMID: 9490675 Free article.

4

The SH2 domain-containing protein tyrosine phosphatase SHP-1 is induced by granulocyte colony-stimulating factor (G-CSF) and modulates signaling from the G-CSF receptor.

Ward AC, Oomen SP, Smith L, Gits J, van Leeuwen D, Soede-Bobok AA, Erpelinck-Verschueren CA, Yi T, Touw IP. Ward AC, et al. Among authors: van leeuwen d. Leukemia. 2000 Jul;14(7):1284-91. doi: 10.1038/sj.leu.2401822. Leukemia. 2000. PMID: 10914554

5

STAT3-mediated differentiation and survival and of myeloid cells in response to granulocyte colony-stimulating factor: role for the cyclin-dependent kinase inhibitor p27(Kip1).

de Koning JP, Soede-Bobok AA, Ward AC, Schelen AM, Antonissen C, van Leeuwen D, Löwenberg B, Touw IP. de Koning JP, et al. Among authors: van leeuwen d. Oncogene. 2000 Jul 6;19(29):3290-8. doi: 10.1038/sj.onc.1203627. Oncogene. 2000. PMID: 10918585

6

Multiple pathways contribute to the hyperproliferative responses from truncated granulocyte colony-stimulating factor receptors.

Gits J, van Leeuwen D, Carroll HP, Touw IP, Ward AC. Gits J, et al. Among authors: van leeuwen d. Leukemia. 2006 Dec;20(12):2111-8. doi: 10.1038/sj.leu.2404448. Epub 2006 Oct 26. Leukemia. 2006. PMID: 17066093

7

EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection.

van Gent M, Griffin BD, Berkhoff EG, van Leeuwen D, Boer IG, Buisson M, Hartgers FC, Burmeister WP, Wiertz EJ, Ressing ME. van Gent M, et al. Among authors: van leeuwen d. J Immunol. 2011 Feb 1;186(3):1694-702. doi: 10.4049/jimmunol.0903120. Epub 2010 Dec 29. J Immunol. 2011. PMID: 21191071

8

Human cytomegalovirus-encoded US2 differentially affects surface expression of MHC class I locus products and targets membrane-bound, but not soluble HLA-G1 for degradation.

Barel MT, Ressing M, Pizzato N, van Leeuwen D, Le Bouteiller P, Lenfant F, Wiertz EJ. Barel MT, et al. Among authors: van leeuwen d. J Immunol. 2003 Dec 15;171(12):6757-65. doi: 10.4049/jimmunol.171.12.6757. J Immunol. 2003. PMID: 14662880

9

A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates.

Hislop AD, Ressing ME, van Leeuwen D, Pudney VA, Horst D, Koppers-Lalic D, Croft NP, Neefjes JJ, Rickinson AB, Wiertz EJ. Hislop AD, et al. Among authors: van leeuwen d. J Exp Med. 2007 Aug 6;204(8):1863-73. doi: 10.1084/jem.20070256. Epub 2007 Jul 9. J Exp Med. 2007. PMID: 17620360 Free PMC article.

We were prompted to readdress this question by recent work (Pudney, V.A., A.M. Leese, A.B. Rickinson, and A.D. Hislop. 2005. J. Exp. Med. 201:349-360; Ressing, M.E., S.E. Keating, D. van Leeuwen, D. ...

We were prompted to readdress this question by recent work (Pudney, V.A., A.M. Leese, A.B. Rickinson, and A.D. Hislop. 2005. J. Exp. …

10

Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion.

Ressing ME, van Leeuwen D, Verreck FA, Keating S, Gomez R, Franken KL, Ottenhoff TH, Spriggs M, Schumacher TN, Hutt-Fletcher LM, Rowe M, Wiertz EJ. Ressing ME, et al. Among authors: van leeuwen d. J Virol. 2005 Jan;79(2):841-52. doi: 10.1128/JVI.79.2.841-852.2005. J Virol. 2005. PMID: 15613312 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

199 results

Search Page

Filters